Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $170.3 million.

  • OptimizeRx's Liabilities and Shareholders Equity rose 310.05% to $170.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $678.5 million, marking a year-over-year decrease of 276.49%. This contributed to the annual value of $171.2 million for FY2024, which is 665.63% down from last year.
  • Latest data reveals that OptimizeRx reported Liabilities and Shareholders Equity of $170.3 million as of Q3 2025, which was up 310.05% from $169.3 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Liabilities and Shareholders Equity ranged from a high of $183.4 million in Q4 2023 and a low of $121.3 million during Q2 2023
  • For the 5-year period, OptimizeRx's Liabilities and Shareholders Equity averaged around $149.7 million, with its median value being $141.0 million (2021).
  • As far as peak fluctuations go, OptimizeRx's Liabilities and Shareholders Equity skyrocketed by 14417.1% in 2021, and later plummeted by 1771.7% in 2023.
  • Over the past 5 years, OptimizeRx's Liabilities and Shareholders Equity (Quarter) stood at $141.0 million in 2021, then dropped by 4.49% to $134.7 million in 2022, then soared by 36.18% to $183.4 million in 2023, then decreased by 6.66% to $171.2 million in 2024, then dropped by 0.49% to $170.3 million in 2025.
  • Its last three reported values are $170.3 million in Q3 2025, $169.3 million for Q2 2025, and $167.8 million during Q1 2025.